| Backwoods (116) |  |
| Forestation (65) | |
| Jungle (83) | |
| Silviculture (9) | |
| Underwood (11) | |
| Backwoods (116) | |
| Forestation (65) | |
| Jungle (83) | |
| Silviculture (9) | |
| Underwood (11) | |
The bowel disease necrotizing enterocolitis (NEC) is the second most common cause of death among premature infants said Mark Underwood lead study author neonatologist and professor in the Department of Pediatrics at UC Davis Children
Underwood and his collaborators evaluated the effectiveness and safety of two types of probiotics of known purity and composition in a clinical trial that included nine breastmilk-and 12 formula-fed premature infants in the Neonatal Intensive care unit (NICU) at UC
and received the B. infantis probiotic Underwood said. No side effects were identified from administration of the two probiotic strains Underwood said.
One of the breastmilk-fed infants treated with B. lactis developed NEC early in the trial Underwood said indicating that B. lactis may not be as effective as B. infantis in protecting against NEC though the study was designed not to answer that question.
Because earlier research conducted in Europe Japan and Australia has demonstrated the potential benefits of probiotic therapy in preventing NEC many NICUS in the United states treat premature infants with the supplements said Underwood.
Probiotic therapy is not however the standard of care for premature infants in the United states. The American Academy of Pediatrics has established not a policy about using the products in newborns
B. lactis colonization was sustained not in the infants Underwood said. The highest total numbers and percentages of bifidobacteria were found after two weeks of B. infantis treatment in the breast milk-fed babies said Underwood.
In addition during the one week break in the phase of the study that involved the breast milk-fed infants the relative abundance of bifidobacteria was significantly greater for those treated with B. infantis.
and composition Underwood said. Specimens were obtained from the stool of the formula-fed infants at baseline the beginning of the study and then weekly for five weeks.
Underwood is submitting an application for a new investigational drug to the FDA for a multi-centered second phase clinical trial to evaluate the safety
and funded by the National institutes of health Underwood and his colleagues will conduct a larger trial. Story Source:
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011